Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429174 | 0.92 | AXL (0.50) | AXLFLT3METAP2PRMT5WDR77 | |
| SCHEMBL13429155 | 0.89 | CCNC (0.47) | AXLFLT3TNKS2METAP2ACVR1 | |
| SCHEMBL13429163 | 0.87 | AXL (0.41) | AXLFLT3TNKS2METAP2PRMT5 | |
| SCHEMBL13429165 | 0.79 | FLT3 (0.48) | FLT3TNKS2ALK | |
| SCHEMBL2008835 | 0.75 | HPGD (0.54) | TNKS2MAPK1 | |
| SCHEMBL13429090 | 0.74 | TNKS2 (0.50) | TNKS2MAPK1BRD4 | |
| SCHEMBL13429131 | 0.73 | ROCK2 (0.43) | FLT3ACVR1 | |
| SCHEMBL13429113 | 0.73 | HPGD (0.57) | TNKS2MAPK1 | |
| SCHEMBL25422299 | 0.72 | CCNC (0.47) | AXLALKCCNCCDK8FYN | |
| SCHEMBL30481247 | 0.72 | CCNC (0.47) | AXLALKCCNCCDK8FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | AXL 680/4885FLT3 595/4885TNKS2 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.